JOHNSON & JOHNSON
JNJAPI behind this page
JNJ FY 2025 request
Playground key active
/api/financials?ticker=JNJ&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 94,193 | 88,821 | +6.0% |
Show Product Lines breakouts |
|||
| Abiomed · MedTech | 1,393 | 1,213 | +14.8% |
| Abiomed · MedTech | 358 | 284 | +26.1% |
| Abiomed · MedTech | 1,751 | 1,496 | +17.0% |
| ADVANCED · MedTech | 1,900 | 1,838 | +3.4% |
| ADVANCED · MedTech | 2,678 | 2,650 | +1.1% |
| ADVANCED · MedTech | 4,577 | 4,488 | +2.0% |
| CAPLYTA · Innovative Medicine | 700 | — | — |
| CAPLYTA · Innovative Medicine | 700 | — | — |
| CARVYKTI · Innovative Medicine | 1,492 | 869 | +71.7% |
| CARVYKTI · Innovative Medicine | 395 | 94 | +320.2% |
| CARVYKTI · Innovative Medicine | 1,887 | 963 | +96.0% |
| CONCERTA/Methylphenidate · Innovative Medicine | 82 | 134 | -38.8% |
| CONCERTA/Methylphenidate · Innovative Medicine | 502 | 507 | -1.0% |
| CONCERTA/Methylphenidate · Innovative Medicine | 584 | 641 | -8.9% |
| CONTACT LENSES/OTHER · MedTech | 1,754 | 1,684 | +4.2% |
| CONTACT LENSES/OTHER · MedTech | 2,157 | 2,049 | +5.3% |
| CONTACT LENSES/OTHER · MedTech | 3,910 | 3,733 | +4.7% |
| DARZALEX · Innovative Medicine | 8,266 | 6,588 | +25.5% |
| DARZALEX · Innovative Medicine | 6,085 | 5,082 | +19.7% |
| DARZALEX · Innovative Medicine | 14,351 | 11,670 | +23.0% |
| EDURANT/rilpivirine · Innovative Medicine | 26 | 31 | -16.1% |
| EDURANT/rilpivirine · Innovative Medicine | 1,461 | 1,241 | +17.7% |
| EDURANT/rilpivirine · Innovative Medicine | 1,486 | 1,272 | +16.8% |
| ELECTROPHYSIOLOGY · MedTech | 2,891 | 2,738 | +5.6% |
| ELECTROPHYSIOLOGY · MedTech | 2,743 | 2,529 | +8.5% |
| ELECTROPHYSIOLOGY · MedTech | 5,634 | 5,267 | +7.0% |
| ERLEADA · Innovative Medicine | 1,453 | 1,282 | +13.3% |
| ERLEADA · Innovative Medicine | 2,121 | 1,717 | +23.5% |
| ERLEADA · Innovative Medicine | 3,574 | 2,999 | +19.2% |
| GENERAL · MedTech | 2,258 | 2,165 | +4.3% |
| GENERAL · MedTech | 3,302 | 3,192 | +3.4% |
| GENERAL · MedTech | 5,560 | 5,358 | +3.8% |
| HIPS · MedTech | 1,080 | 1,057 | +2.2% |
| HIPS · MedTech | 594 | 581 | +2.2% |
| HIPS · MedTech | 1,674 | 1,638 | +2.2% |
| IMBRUVICA · Innovative Medicine | 892 | 1,020 | -12.5% |
| IMBRUVICA · Innovative Medicine | 1,931 | 2,018 | -4.3% |
| IMBRUVICA · Innovative Medicine | 2,823 | 3,038 | -7.1% |
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA · Innovative Medicine | 2,725 | 3,125 | -12.8% |
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA · Innovative Medicine | 1,085 | 1,097 | -1.1% |
| INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA · Innovative Medicine | 3,810 | 4,222 | -9.8% |
| KNEES · MedTech | 924 | 922 | +0.2% |
| KNEES · MedTech | 663 | 623 | +6.4% |
| KNEES · MedTech | 1,587 | 1,545 | +2.7% |
| OPSUMIT · Innovative Medicine | 1,633 | 1,557 | +4.9% |
| OPSUMIT · Innovative Medicine | 692 | 668 | +3.6% |
| OPSUMIT · Innovative Medicine | 2,325 | 2,225 | +4.5% |
| other cardiovascular · MedTech | 124 | 120 | +3.3% |
| other cardiovascular · MedTech | 273 | 260 | +5.0% |
| other cardiovascular · MedTech | 397 | 380 | +4.5% |
| Other Immunology · Innovative Medicine | 59 | 3 | +1866.7% |
| Other Immunology · Innovative Medicine | 2 | 0 | — |
| Other Immunology · Innovative Medicine | 61 | 3 | +1933.3% |
| Other Infectious Diseases · Innovative Medicine | 12 | 11 | +9.1% |
| Other Infectious Diseases · Innovative Medicine | 163 | 401 | -59.4% |
| Other Infectious Diseases · Innovative Medicine | 175 | 412 | -57.5% |
| OTHER NEUROSCIENCE · Innovative Medicine | 159 | 210 | -24.3% |
| OTHER NEUROSCIENCE · Innovative Medicine | 889 | 965 | -7.9% |
| OTHER NEUROSCIENCE · Innovative Medicine | 1,048 | 1,175 | -10.8% |
| Other Oncology · Innovative Medicine | 214 | 145 | +47.6% |
| Other Oncology · Innovative Medicine | 162 | 172 | -5.8% |
| Other Oncology · Innovative Medicine | 376 | 317 | +18.6% |
| Other Pulmonary Hypertension · Innovative Medicine | 54 | 75 | -28.0% |
| Other Pulmonary Hypertension · Innovative Medicine | 155 | 165 | -6.1% |
| Other Pulmonary Hypertension · Innovative Medicine | 209 | 240 | -12.9% |
| Other · Innovative Medicine | 542 | 494 | +9.7% |
| Other · Innovative Medicine | 603 | 696 | -13.4% |
| Other · Innovative Medicine | 1,145 | 1,189 | -3.7% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 1,226 | 1,311 | -6.5% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 353 | 401 | -12.0% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 1,579 | 1,712 | -7.8% |
| Remicade · Innovative Medicine | 1,171 | 1,009 | +16.1% |
| Remicade · Innovative Medicine | 74 | 98 | -24.5% |
| Remicade · Innovative Medicine | 523 | 497 | +5.2% |
| Remicade · Innovative Medicine | 1,768 | 1,605 | +10.2% |
| RYBREVANT/LAZCLUZE · Innovative Medicine | 534 | 257 | +107.8% |
| RYBREVANT/LAZCLUZE · Innovative Medicine | 200 | 70 | +185.7% |
| RYBREVANT/LAZCLUZE · Innovative Medicine | 734 | 327 | +124.5% |
| Shockwave Medical, Inc. · MedTech | 897 | 442 | +102.9% |
| Shockwave Medical, Inc. · MedTech | 249 | 122 | +104.1% |
| Shockwave Medical, Inc. · MedTech | 1,146 | 564 | +103.2% |
| Simponi/Simponi Aria · Innovative Medicine | 1,193 | 1,082 | +10.3% |
| Simponi/Simponi Aria · Innovative Medicine | 1,475 | 1,108 | +33.1% |
| Simponi/Simponi Aria · Innovative Medicine | 2,668 | 2,190 | +21.8% |
| SPINE,SPORTS & OTHER · MedTech | 1,658 | 1,696 | -2.2% |
| SPINE,SPORTS & OTHER · MedTech | 1,193 | 1,230 | -3.0% |
| SPINE,SPORTS & OTHER · MedTech | 2,852 | 2,926 | -2.5% |
| SPRAVATO · Innovative Medicine | 1,485 | 929 | +59.8% |
| SPRAVATO · Innovative Medicine | 210 | 148 | +41.9% |
| SPRAVATO · Innovative Medicine | 1,696 | 1,077 | +57.5% |
| Stelara · Innovative Medicine | 3,847 | 6,720 | -42.8% |
| Stelara · Innovative Medicine | 2,230 | 3,641 | -38.8% |
| Stelara · Innovative Medicine | 6,078 | 10,361 | -41.3% |
| SURGICAL · MedTech | 471 | 444 | +6.1% |
| SURGICAL · MedTech | 1,086 | 969 | +12.1% |
| SURGICAL · MedTech | 1,558 | 1,413 | +10.3% |
| TALVEY · Innovative Medicine | 340 | 241 | +41.1% |
| TALVEY · Innovative Medicine | 123 | 46 | +167.4% |
| TALVEY · Innovative Medicine | 463 | 287 | +61.3% |
| TECVAYLI · Pharmaceutical | 444 | 418 | +6.2% |
| TECVAYLI · Pharmaceutical | 226 | 131 | +72.5% |
| TECVAYLI · Pharmaceutical | 670 | 549 | +22.0% |
| TRAUMA · MedTech | 2,058 | 2,013 | +2.2% |
| TRAUMA · MedTech | 1,088 | 1,036 | +5.0% |
| TRAUMA · MedTech | 3,146 | 3,049 | +3.2% |
| Tremfya · Innovative Medicine | 3,529 | 2,443 | +44.5% |
| Tremfya · Innovative Medicine | 1,626 | 1,227 | +32.5% |
| Tremfya · Innovative Medicine | 5,155 | 3,670 | +40.5% |
| UPTRAVI · Innovative Medicine | 1,536 | 1,511 | +1.7% |
| UPTRAVI · Innovative Medicine | 366 | 307 | +19.2% |
| UPTRAVI · Innovative Medicine | 1,902 | 1,817 | +4.7% |
| XARELTO · Innovative Medicine | 2,633 | 2,373 | +11.0% |
| XARELTO · Innovative Medicine | 2,633 | 2,373 | +11.0% |
| ZYTIGA/abiraterone acetate · Innovative Medicine | 23 | 34 | -32.4% |
| ZYTIGA/abiraterone acetate · Innovative Medicine | 480 | 597 | -19.6% |
| ZYTIGA/abiraterone acetate · Innovative Medicine | 502 | 631 | -20.4% |
Show Business Segments breakouts |
|||
| Innovative Medicine | 60,401 | 56,964 | +6.0% |
| Innovative Medicine · Cardiovascular/Metabolism/Other | 3,778 | 3,562 | +6.1% |
| Innovative Medicine · Immunology | 15,728 | 17,828 | -11.8% |
| Innovative Medicine · Infectious Diseases | 3,241 | 3,396 | -4.6% |
| Innovative Medicine · Neuroscience | 7,837 | 7,115 | +10.1% |
| Innovative Medicine · Non Us | 24,057 | 22,994 | +4.6% |
| Innovative Medicine · Non Us | 603 | 696 | -13.4% |
| Innovative Medicine · Non Us | 5,856 | 6,473 | -9.5% |
| Innovative Medicine · Non Us | 1,977 | 2,042 | -3.2% |
| Innovative Medicine · Non Us | 2,686 | 2,718 | -1.2% |
| Innovative Medicine · Non Us | 11,721 | 9,926 | +18.1% |
| Innovative Medicine · Non Us | 1,214 | 1,140 | +6.5% |
| Innovative Medicine · Oncology | 25,380 | 20,781 | +22.1% |
| Innovative Medicine · Operating Segments | 60,401 | 56,964 | +6.0% |
| Innovative Medicine · Pulmonary Hypertension | 4,437 | 4,282 | +3.6% |
| Innovative Medicine · US | 36,344 | 33,970 | +7.0% |
| Innovative Medicine · US | 3,175 | 2,866 | +10.8% |
| Innovative Medicine · US | 9,872 | 11,355 | -13.1% |
| Innovative Medicine · US | 1,264 | 1,354 | -6.6% |
| Innovative Medicine · US | 5,151 | 4,398 | +17.1% |
| Innovative Medicine · US | 13,659 | 10,854 | +25.8% |
| Innovative Medicine · US | 3,223 | 3,143 | +2.5% |
| MedTech | 33,792 | 31,857 | +6.1% |
| MedTech · Cardiovascular | 8,928 | 7,707 | +15.8% |
| MedTech · Non Us | 16,384 | 15,525 | +5.5% |
| MedTech · Non Us | 3,623 | 3,194 | +13.4% |
| MedTech · Non Us | 3,538 | 3,470 | +2.0% |
| MedTech · Non Us | 5,980 | 5,842 | +2.4% |
| MedTech · Non Us | 3,243 | 3,018 | +7.5% |
| MedTech · Operating Segments | 33,792 | 31,857 | +6.1% |
| MedTech · Orthopaedics | 9,258 | 9,158 | +1.1% |
| MedTech · Surgery | 10,137 | 9,845 | +3.0% |
| MedTech · US | 17,408 | 16,332 | +6.6% |
| MedTech · US | 5,305 | 4,513 | +17.5% |
| MedTech · US | 5,720 | 5,689 | +0.5% |
| MedTech · US | 4,157 | 4,003 | +3.8% |
| MedTech · US | 2,225 | 2,128 | +4.6% |
| MedTech · Vision | 5,468 | 5,146 | +6.3% |
Show Geography breakouts |
|||
| Asia-Pacific, Africa · Operating Segments | 14,031 | 13,593 | +3.2% |
| Europe · Operating Segments | 21,535 | 20,212 | +6.5% |
| Non Us | 40,441 | 38,519 | +5.0% |
| US | 53,752 | 50,302 | +6.9% |
| US · Operating Segments | 53,752 | 50,302 | +6.9% |
| Western Hemisphere excluding U.S. · Operating Segments | 4,875 | 4,714 | +3.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 94,193 | 88,821 | +6.0% |
| Cost of Revenue | 30,256 | 27,471 | +10.1% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 15,646 | 14,036 | +11.5% |
| MedTech · Operating Segments | 14,549 | 13,345 | +9.0% |
| Gross Profit | 63,937 | 61,350 | +4.2% |
| Selling, General & Administrative | 23,676 | 22,869 | +3.5% |
Show Product Lines breakouts |
|||
| Shipping And Handling | 0.9 | 0.9 | 0.0% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 11,375 | 10,906 | +4.3% |
| MedTech · Operating Segments | 11,354 | 10,812 | +5.0% |
| Research And Development Expense Excluding Acquired In Process Cost | 14,665 | 17,232 | -14.9% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 11,827 | 13,529 | -12.6% |
| MedTech · Operating Segments | 2,838 | 3,703 | -23.4% |
| Research And Development In Process1 | 81 | 211 | -61.6% |
| Interest Income | -1,056 | -1,332 | +20.7% |
| Interest Expense | 971 | 755 | +28.6% |
| Other Non-Operating Income (Expense) | -7,209 | 4,694 | -253.6% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 713 | 426 | +67.4% |
| MedTech · Operating Segments | -938 | -257 | -265.0% |
| Restructuring Charges | 228 | 234 | -2.6% |
Show Business Segments breakouts |
|||
| Medtech Ortho Franchise · Costs of Goods and Services Sold | 84 | 35 | +140.0% |
| Medtech Ortho Franchise · Other (Income) Expense | 71 | — | — |
| Medtech Ortho Franchise · Restructuring Charges | 152 | 132 | +15.2% |
| Medtech Surgery Franchise · Costs of Goods and Services Sold | 7 | — | — |
| Medtech Surgery Franchise · Operating Segments | 205 | — | — |
| Medtech Surgery Franchise · Other (Income) Expense | 122 | — | — |
| Medtech Surgery Franchise · Restructuring Charges | 76 | — | — |
| MedTech · Operating Segments | 0.5 | 0.2 | +150.0% |
| Orthopaedics Restructuring Plan · Operating Segments | 307 | — | — |
Show Consolidation Items breakouts |
|||
| Operating Segments | 512 | 269 | +90.3% |
Show Restructuring Plan breakouts |
|||
| Orthopaedics Restructuring Plan | 0.3 | 0.2 | +50.0% |
| Surgery Restructuring Plan | 0.2 | — | — |
| Income Before Taxes | 32,581 | 16,687 | +95.2% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 22,266 | 18,919 | +17.7% |
| MedTech · Operating Segments | 4,113 | 3,740 | +10.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 26,379 | 22,659 | +16.4% |
| Income Tax Expense (Benefit) | 5,777 | 2,621 | +120.4% |
| Income Loss From Continuing Operations | 26,804 | 14,066 | +90.6% |
| Net Income | 26,804 | 14,066 | +90.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | 26,804 | 14,066 | +90.6% |
| Income Loss From Continuing Operations Per Basic Share | 11.13 | 5.84 | +90.6% |
| EPS (Basic) | 11.13 | 5.84 | +90.6% |
| Income Loss From Continuing Operations Per Diluted Share | 11.03 | 5.79 | +90.5% |
| EPS (Diluted) | 11.03 | 5.79 | +90.5% |
| Wtd Avg Shares (Basic) | 2,407.4 | 2,407.3 | 0.0% |
| Wtd Avg Shares (Diluted) | 2,429.4 | 2,429.4 | 0.0% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 1,953 | -511 | +482.2% |
Show Derivative Risk breakouts |
|||
| Cross Currency Interest Rate Contract · Cash Flow Hedging | 1,187 | -597 | +298.8% |
| Foreign Exchange Contract · Cash Flow Hedging | -44 | 21 | -309.5% |
| Foreign Exchange Contract · Cash Flow Hedging | 715 | -156 | +558.3% |
| Foreign Exchange Contract · Cash Flow Hedging | -109 | 80 | -236.2% |
| Foreign Exchange Contract · Cash Flow Hedging | 11 | -7 | +257.1% |
| Foreign Currency Transaction Gain Loss Before Tax | -254 | -214 | -18.7% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 19,709 | 24,105 | -18.2% |
Show Fair Value Hierarchy breakouts |
|||
| Fair Value Inputs Level1 · Money Market Funds | 5,993 | 6,123 | -2.1% |
Show Financial Instrument breakouts |
|||
| Bank Time Deposits · Heldtomaturity Securities | 893 | 1,045 | -14.5% |
| Cash · Heldtomaturity Securities | 3,299 | 2,918 | +13.1% |
| Corporate Debt Securities · Availableforsale Securities | 35 | 40 | -12.5% |
| Money Market Funds · Heldtomaturity Securities | 5,993 | 6,123 | -2.1% |
| Securities Loaned Or Sold Under Agreements To Repurchase · Heldtomaturity Securities | 7,063 | 7,100 | -0.5% |
| Sovereign Debt Securities · Availableforsale Securities | 102 | 83 | +22.9% |
| US Treasury And Government · Availableforsale Securities | 2,324 | 6,796 | -65.8% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 2,461 | 6,919 | -64.4% |
| Heldtomaturity Securities | 17,248 | 17,186 | +0.4% |
| Marketable Securities (Current) | 393 | 417 | -5.8% |
Show Financial Instrument breakouts |
|||
| Corporate Debt Securities · Availableforsale Securities | 194 | 184 | +5.4% |
| Sovereign Debt Securities · Availableforsale Securities | 158 | 93 | +69.9% |
| US Treasury And Government · Availableforsale Securities | 41 | 20 | +105.0% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 393 | 297 | +32.3% |
| Accounts Receivable | 17,178 | 14,842 | +15.7% |
| Inventory | 14,191 | 12,444 | +14.0% |
| Prepaid Expenses & Other Current Assets | 4,153 | 4,085 | +1.7% |
| Total Current Assets | 55,624 | 55,893 | -0.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 23,169 | 20,518 | +12.9% |
| Goodwill | 48,772 | 44,200 | +10.3% |
Show Business Segments breakouts |
|||
| Innovative Medicine | 14,967 | 10,692 | +40.0% |
| MedTech | 33,805 | 33,508 | +0.9% |
| Deferred Tax Assets | 6,874 | 10,461 | -34.3% |
| Other Non-Current Assets | 14,368 | 11,414 | +25.9% |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 665 | 451 | +47.5% |
| Equity Securities · Equity Investments without readily determinable value | 910 | 773 | +17.7% |
| Total Assets | 199,210 | 180,104 | +10.6% |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 34,671 | 38,712 | -10.4% |
| Innovative Medicine · Operating Segments | 78,057 | 57,070 | +36.8% |
| MedTech · Operating Segments | 86,482 | 84,322 | +2.6% |
| Segments Total | 164,539 | 141,392 | +16.4% |
| Operating Lease Right-of-Use Assets | 1.3 | 1.1 | +18.2% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 6,363 | 6,766 | -6.0% |
| Patents And Trademarks | 26,649 | 18,571 | +43.5% |
| Marketable Securities (Non-Current) (Q) | — | — | — |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 665 | 451 | +47.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 50,403 | 37,618 | +34.0% |
| Current Liabilities | |||
| Short Term Borrowings | 8,495 | 5,983 | +42.0% |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 6.5 | 4.1 | +58.5% |
| Accounts Payable | 11,991 | 10,311 | +16.3% |
| Accrued Liabilities | 8,594 | 8,549 | +0.5% |
| Accrued Rebates Returns And Promotions | 19,124 | 17,580 | +8.8% |
Show Business Segments breakouts |
|||
| Pharmaceutical | 13 | 12.3 | +5.7% |
| Employee Related Liabilities Current | 4,534 | 4,126 | +9.9% |
| Accrued Income Taxes Current | 1,388 | 3,772 | -63.2% |
| Total Current Liabilities | 54,126 | 50,321 | +7.6% |
| Current Portion of Long-Term Debt | 2,000 | 1,749 | +14.4% |
| Debt Current | 8.5 | 6 | +41.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 39,438 | 30,651 | +28.7% |
| Deferred Tax Liabilities | 6,791 | 2,448 | +177.4% |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 6,957 | 7,255 | -4.1% |
Show Retirement Plan Type breakouts |
|||
| Other Postretirement Benefit Plans Defined Benefit | 3,607 | 3,879 | -7.0% |
| Pension Plans Defined Benefit | 2,773 | 2,832 | -2.1% |
| Accrued Income Taxes Noncurrent | 486 | 390 | +24.6% |
| Other Non-Current Liabilities | 9,868 | 17,549 | -43.8% |
| Total Liabilities | 117,666 | 108,614 | +8.3% |
| Long-Term Debt | 41,438 | 32,400 | +27.9% |
Show Debt Instrument breakouts |
|||
| 0.95% Notes due 2027 | 1,499 | 1,458 | +2.8% |
| 1.150% Notes due 2028 (750MM Euro 1.1785)(1)/(750MM Euro 1.0401)(2) | 882 | 777 | +13.5% |
| 1.30% Notes due 2030 | 1,693 | 1,646 | +2.9% |
| 1.650% Notes due 2035 (1.5B Euro 1.1785)(1)/(1.5B Euro 1.0401)(2) | 1,758 | 1,550 | +13.4% |
| 2.10% Notes due 2040 | 898 | 845 | +6.3% |
| 2.25% Notes due 2050 | 861 | 808 | +6.6% |
| 2.45% Notes due 2026 | 2,000 | 1,999 | +0.1% |
| 2.45% Notes due 2060 | 1,112 | 1,058 | +5.1% |
| 2.700% Notes Due 2029 | 707 | — | — |
| 2.90% Notes due 2028 | 1,498 | 1,498 | 0.0% |
| 2.95% Notes due 2027 | 968 | 927 | +4.4% |
| 3.05% Notes due 2033 | 823 | — | — |
| 3.20% Notes due 2032 | 822 | 725 | +13.4% |
| 3.35% Notes due 2036 | 938 | 827 | +13.4% |
| 3.35% Notes due 2037 | 1,176 | — | — |
| 3.40% Notes due 2038 | 994 | 993 | +0.1% |
| 3.50% Notes due 2048 | 744 | 744 | 0.0% |
| 3.55% Notes due 2044 | 1,168 | 1,030 | +13.4% |
| 3.587% Notes due 2036 | 919 | 869 | +5.8% |
| 3.60% Notes due 2045 | 819 | — | — |
| 3.625% Notes due 2037 | 1,409 | 1,358 | +3.8% |
| 3.70% Notes due 2055 | 1,173 | — | — |
| 3.73% Notes due 2046 | 1,979 | 1,978 | +0.1% |
| 3.75% Notes due 2047 | 876 | 822 | +6.6% |
| 4.375% Notes due 2033 | 853 | 854 | -0.1% |
| 4.50% Notes due 2027 | 749 | — | — |
| 4.50% Notes due 2043 | 497 | 496 | +0.2% |
| 4.50% Notes due 2040 | 542 | 541 | +0.2% |
| 4.55% Notes Due 2028 | 748 | — | — |
| 4.70% Notes due 2030 | 996 | — | — |
| 4.80% Notes due 2029 | 1,147 | 1,146 | +0.1% |
| 4.85% Notes due 2032 | 1,243 | — | — |
| 4.85% Notes due 2041 | 298 | 297 | +0.3% |
| 4.90% Notes due 2031 | 1,146 | 1,145 | +0.1% |
| 4.95% Notes due 2034 | 847 | 846 | +0.1% |
| 4.95% Notes due 2033 | 499 | 499 | 0.0% |
| 5.00% Notes Due 2035 | 1,244 | — | — |
| 5.25% Notes due 2054 | 843 | 843 | 0.0% |
| 5.85% Notes due 2038 | 697 | 697 | 0.0% |
| 5.95% Notes due 2037 | 995 | 994 | +0.1% |
| 6.95% Notes due 2029 | 299 | 298 | +0.3% |
| Other Debt Securities | 79 | 83 | -4.8% |
| Stockholders' Equity | |||
| Common Stock | 3,120 | 3,120 | 0.0% |
| Accumulated Other Comprehensive Income | -14,930 | -11,741 | -27.2% |
| Retained Earnings | 168,978 | 155,791 | +8.5% |
| Treasury Stock Value | 75,624 | 75,680 | -0.1% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 81,544 | 71,490 | +14.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -693 | -1,551 | +55.3% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -290 | -1,750 | +83.4% |
| Accumulated Other Comprehensive Income | -14,930 | -11,741 | -27.2% |
| Accumulated Translation Adjustment | -13,947 | -8,441 | -65.2% |
| Common Stock | 3,120 | 3,120 | 0.0% |
| Retained Earnings | 168,978 | 155,791 | +8.5% |
| Treasury Stock Common | -75,624 | -75,680 | +0.1% |
| Total Liabilities & Equity | 199,210 | 180,104 | +10.6% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 7,503 | 7,339 | +2.2% |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 241 | 342 | -29.5% |
| Innovative Medicine · Operating Segments | 3,772 | 3,760 | +0.3% |
| MedTech · Operating Segments | 3,490 | 3,237 | +7.8% |
| Segments Total | 7,262 | 6,997 | +3.8% |
| Stock-Based Compensation | 1,354 | 1,176 | +15.1% |
| Asset Impairment Charges | 204 | 405 | -49.6% |
| Research & Development | 109 | 1,841 | -94.1% |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | -263 | -226 | -16.4% |
| Deferred Income Taxes | 1,538 | -2,183 | +170.5% |
| Provision For Doubtful Accounts | -1 | 11 | -109.1% |
| Change in Accounts Receivable | -1,781 | -406 | -338.7% |
| Change in Inventory | -1,450 | -1,128 | -28.5% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 2,377 | 1,621 | +46.6% |
| Increase Decrease In Other Operating Assets | -6,167 | 1,717 | -459.2% |
| Increase Decrease In Other Operating Liabilities | -5,697 | 33 | -17363.6% |
| Net Cash from Operations | 24,530 | 24,266 | +1.1% |
| Investing Activities | |||
| Capital Expenditures | -4,832 | -4,424 | -9.2% |
| Proceeds From Sale Of Productive Assets | 720 | 675 | +6.7% |
| Payments To Acquire Businesses Net Of Cash Acquired | -17,541 | -15,146 | -15.8% |
| Payments To Acquired In Process Research And Development Assets | -385 | -1,783 | +78.4% |
| Payments To Acquire Investments | -920 | -1,726 | +46.7% |
| Proceeds From Sale Maturity And Collections Of Investments | 1,661 | 2,462 | -32.5% |
| Proceeds Payments From To Credit Support Agreements Investing Activities | -2,129 | 1,517 | -240.3% |
| Other Investing Activities | -162 | -174 | +6.9% |
| Net Cash from Investing | -23,588 | -18,599 | -26.8% |
| Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds | 2,591 | 1,551 | +67.1% |
| Financing Activities | |||
| Payments Of Ordinary Dividends | -12,381 | -11,823 | -4.7% |
| Share Repurchases | -5,953 | -2,432 | -144.8% |
| Proceeds From Short Term Debt | 14,586 | 15,277 | -4.5% |
| Repayments Of Short Term Debt | -12,330 | -9,463 | -30.3% |
| Proceeds From Issuance Of Long Term Debt | 9,138 | 6,660 | +37.2% |
| Repayments Of Long Term Debt | -1,757 | -1,453 | -20.9% |
| Proceeds From Exercise Of Stock Options And Excess Tax Benefits | 3,418 | 838 | +307.9% |
| Proceeds Payments From To Credit Support Agreements Financing Activities | -226 | 272 | -183.1% |
| Proceeds From Payments For Other Financing Activities | -34 | -38 | +10.5% |
| Net Cash from Financing | -5,539 | -3,132 | -76.9% |
| Supplemental | |||
| Interest Paid | 1,977 | 1,990 | -0.7% |
| Interest Paid | 1,863 | 1,911 | -2.5% |
| Income Taxes Paid | 6,539 | 6,714 | -2.6% |
| Income Taxes Paid | 6,539 | 6,714 | -2.6% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 201 | -289 | +169.6% |
| Net Change in Cash | -4,396 | 2,246 | -295.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Continuing Operations | 19,709 | 24,105 | -18.2% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 19,709 | 24,105 | -18.2% |
Values in millions USD. Source: SEC EDGAR 10-K filing.